ChemoCentryx   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Mountain View CA United States (1997)
Status: Acquired by Amgen (2022)

Organization Overview

First Clinical Trial
2004
NCT00102921
First Marketed Drug
2021
avacopan (Tavneos)
First NDA Approval
2021
avacopan (Tavneos)
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

ChemoCentryx | CHEMOCENTRYX | ChemoCentryx Inc | ChemoCentryx, Inc | ChemoCentryx, Inc.

Active Ingredients

Marketed Drugs (1)

avacopan (Tavneos) (2021 NDA)

Drugs in Phase 3 Trials (5)

avacopan (Tavneos) (7 trials)

azathioprine (imuran) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

prednisone (meticorten) (1 trial)

rituximab (rituxan) (1 trial)

Drugs in Phase 2 Trials (4)

ccx-140 (5 trials)

ccx-354 (2 trials)

pioglitazone (actos) (1 trial)

verecimon (3 trials)

Drugs in Phase 1 Trials (1)

ccx872-b (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 1)

Albuminuria (Phase 2)

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (Phase 3)

Arthritis (Phase 2)

Arthritis, Rheumatoid (Phase 2)

Atypical Hemolytic Uremic Syndrome (Phase 2)

Azotemia (Phase 2)

Celiac Disease (Phase 2)

Crohn Disease (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Diabetic Nephropathies (Phase 2)

Glomerulonephritis, IGA (Phase 2)

Glomerulosclerosis, Focal Segmental (Phase 2)

Hemolysis (Phase 2)

Hemolytic-Uremic Syndrome (Phase 2)

Hidradenitis (Phase 2)

Hidradenitis Suppurativa (Phase 2)

Kidney Diseases (Phase 2)

Nephrosis (Phase 2)

Nephrotic Syndrome (Phase 2)

Syndrome (Phase 2)

Vasculitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial APIs: 10